Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Phase 2 Prospective, Randomized, Controlled Study of CLT-008 Myeloid Progenitor Cells as a Supportive Care Measure During Induction Chemotherapy for Acute Myeloid Leukemia

NCT02282215 is registered in ClinicalTrials.gov with Cellerant Therapeutics as lead sponsor.

NCT NCT02282215
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02282215 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Phase 2 Prospective, Randomized, Controlled Study of CLT-008 Myeloid Progenitor Cells as a Supportive Care Measure During Induction Chemotherapy for Acute Myeloid Leukemia
Lead sponsor
Cellerant Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2014
Completion date
September 22, 2017
Enrollment
163 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, infection, neutropenia